Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNTech SE's revenue for the
three
months ended in Mar. 2026 was R$714 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was R$17,740 Mil.
BioNTech SE's Revenue per Share for the
three
months ended in Mar. 2026 was R$0.18.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was R$4.59.
Warning Sign:
BioNTech SE revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of BioNTech SE was 10.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -42.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 4.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 10 years, BioNTech SE's highest 3-Year average Revenue per Share Growth Rate was 405.30% per year. The lowest was -47.40% per year. And the median was 94.10% per year.
BioNTech SE (BSP:B1NT34) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
BioNTech SE Revenue Related Terms
BioNTech SE Revenue Historical Data
* Premium members only.
The historical data trend for BioNTech SE's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:B1NT34 vs INCY, INSM, ROIV: Revenue Comparison
For the Biotechnology subindustry, BioNTech SE's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's Revenue distribution charts can be found below:
* The bar in red indicates where BioNTech SE's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$17,740 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNTech SE (BSP:B1NT34) has a Revenue of R$17,740 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on BioNTech SE and its competitors.
Is BioNTech SE's Revenue too high?
BioNTech SE's current Revenue is R$17,740 Mil. Overall, BioNTech SE has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's Revenue compare to INCY and INSM?
BioNTech SE's Revenue of R$17,740 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on BioNTech SE and its competitors. BioNTech SE's current Revenue is R$17,740 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BSP:B1NT34) is currently considered Fairly Valued. The stock's GF Value™ is R$27.13, compared to a current price of R$29.28 — trading 7.9% above its estimated fair value. The current Revenue is R$17,740 Mil. BioNTech SE's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For BioNTech SE (BSP:B1NT34), the current Revenue is R$17,740 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (BSP:B1NT34) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of R$29.28 is trading 7.9% above its estimated GF Value™ of R$27.13.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for BSP:B1NT34:
Revenue: R$17,740 Mil
GF Value™: R$27.13 vs. price of R$29.28 (7.9% above fair value)
No single metric tells the full story. See the BSP:B1NT34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
53GF Score
Get the complete analysis for BSP:B1NT34
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:B1NT34 has been successfully added to your 
